Merck & Co., Inc. $MRK Shares Sold by Boston Trust Walden Corp

Boston Trust Walden Corp reduced its stake in Merck & Co., Inc. by 3.0% in Q4, selling 14,563 shares, now holding 465,618 shares valued at approximately $49.01 million. This comes as Merck’s shares dropped 3.8% following the failure of a late-stage oncology combination therapy to meet primary endpoints, though the company exceeded quarterly EPS expectations and received several regulatory approvals. Despite the clinical setback, Merck issued positive FY2026 earnings guidance and maintains a 3.0% dividend yield.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments